Incorporation of the Company. Established the first plant for oral dosage in Haridwar, Uttarakhand.
Established a dedicated manufacturing site for oral liquid dosage.
2007-2010
Expansion
Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals.
Dedicated a facility for hormones, cosmetics, and dermatology.
2010-2012
Innovations
Innovated bi-layered sustained release tablets for the first time.
Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities.
2012-2015
Market Expansion
Innovated tablet-in-tablet sustained release tablets for the first time. Acquired Malik Lifesciences Private
Limited manufacturing sites to expand capacity and capabilities. Expanded into the African market.
Expanded into the Asian market. Established a research and development laboratory in Mumbai,
Maharashtra to venture into the regulated market.
2015-2019
Certifications & Investments
Maxcure Nutravedics Limited received US-NSF certification.
Investment by Ruby Quadria Capital Investment Holdings Pte. Ltd. in Akums, becoming a minority
shareholder.
2019-2022
European Accreditation
Started Akums Lifesciences Limited to venture into APIs. Acquisition of a facility at Kotdwar, Uttarakhand
by Akums Healthcare Limited.
Two manufacturing plants accredited with European Union Good Manufacturing Practices, qualifying for
exports to European markets. Acquisition of facilities in Haridwar and Baddi, Himachal Pradesh by Pure and
Cure Healthcare Private Limited.
2022-2023
Acquisitions & Mergers
Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited.
Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited.
2023-2024
IPO Listing
Akums achieved a major milestone by going public, reflecting its significant growth and solidifying its leadership in the pharmaceutical industry. The IPO marks a new era for Akums, enabling further expansion and innovation on a global scale.
